![](/img/cover-not-exists.png)
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers
Park, Ji Hyun, Kang, Myung Joo, Ahn, Jin-Hee, Kim, Jeong Eun, Jung, Kyung Hae, Gong, Gyungyub, Lee, Hee Jin, Son, Byung-Ho, Ahn, Sei-Hyun, Kim, Hak-Hee, Shin, Hee Jung, Moon, Dae-Hyuk, Kim, Sung-BaeVolume:
78
Language:
english
Journal:
Cancer Chemotherapy and Pharmacology
DOI:
10.1007/s00280-016-3107-6
Date:
October, 2016
File:
PDF, 999 KB
english, 2016